Product information and disease description Place of product in therapy Approaches to treatment

Place in treatment, anticipated use, and care setting

14 evidence topics · 14 sources

Summary

Tavapadon was studied in 2 settings. As monotherapy in early Parkinson's disease, TEMPO-1 (529 participants) and TEMPO-2 (304 participants) enrolled adults aged 40 to 80 years with disease duration under 3 years who were treatment-naive or had less than 3 months of prior dopaminergic treatment. As an adjunct to levodopa, TEMPO-3 (507 participants) enrolled adults with motor fluctuations on a fixed levodopa dose. The company describes the drug as studied as a once-daily oral treatment.

In early disease, tavapadon enters a setting in which the AAN guideline asks clinicians to counsel on the benefits and risks of levodopa, dopamine agonists, and MAO-B inhibitors, permits a dopamine agonist as initial therapy in select patients younger than 60 years at higher risk of dyskinesia, and advises against dopamine agonists in patients older than 70 years or with impulse control disorders, cognitive impairment, excessive daytime sleepiness, or hallucinations.

As an adjunct, tavapadon joins dopamine agonists, MAO-B inhibitors, COMT inhibitors, extended-release amantadine, and istradefylline. In pooled analyses, oral adjunct classes reduce off-time by 0.8 to 1.1 hours per day relative to placebo; TEMPO-3 reported a 1.1-hour increase in good on-time relative to placebo.

The proposed differentiation is D1/D5 selectivity, hypothesized to lower the risk of impulse control disorders, somnolence, and other adverse events attributed to D2/D3 stimulation. A 2026 meta-analysis rated the estimates for impulse control disorder (relative risk 2.02, 95% CI 0.51 to 8.00; 1 trial) and somnolence (pooled relative risk 1.20, 95% CI 0.37 to 3.92) as very low certainty and found that no trial used an active comparator or lasted longer than 27 weeks. A 2026 review stated that studies of drugs selectively targeting D1 receptors do not support improved safety and tolerability.

NICE advises seeking specialist advice before modifying therapy once dyskinesia or motor fluctuations develop. Analysts quoted at approval expected gradual uptake while Medicare coverage was negotiated.

Populations studied in the TEMPO trials

“This includes two Phase 3 trials (TEMPO-1 and TEMPO-2) in early Parkinson's disease, and one Phase 3 trial (TEMPO-3) with tavapadon as adjunctive to levodopa in patients experiencing motor fluctuations.” (opens the source at this quote in a new tab)
“TEMPO-1 and -2 enrolled patients with early Parkinson's disease (with or without an MAO-B inhibitor) and TEMPO-3 enrolled patients who are on fixed-dose levodopa and had motor fluctuations.” (opens the source at this quote in a new tab)
“For many people living with Parkinson's disease, today's oral standard of care isn't effective enough to manage symptoms” (opens the source at this quote in a new tab)

Place in therapy stated in a 2026 review

“A novel D1 dopamine agonist (tavapadon) has completed late stage clinical development showing efficacy both as monotherapy in early PD and as adjunct to levodopa in patients with motor fluctuations.” (opens the source at this quote in a new tab)
“Tavapadon is a novel selective long-acting dopamine D1/D5 receptor partial agonist suitable for once daily oral administration” (opens the source at this quote in a new tab)
“The prime unmet needs regarding current D2-agonist treatment relate to their AE-profile, in particular regarding daytime somnolence, psychosis and impulse dyscontrol.” (opens the source at this quote in a new tab)
“While the above studies support the antiparkinsonian efficacy of drugs selectively targeting D1-receptors they do not support improved safety and tolerability.” (opens the source at this quote in a new tab)
“Longer term data will be required to assess ICD and dyskinesia risk.” (opens the source at this quote in a new tab)

Unmet need in early disease addressed by the monotherapy trials

“Oral levodopa is the preferred initial treatment for PD, but its long-term use is associated with development of motor complications, including so-called on-off fluctuations and dyskinesias.” (opens the source at this quote in a new tab)
“Therefore, there is a key unmet need for an early PD therapy that improves motor symptoms while reducing the risk of AEs seen with current dopaminergic therapies.” (opens the source at this quote in a new tab)
“By selectively targeting D1/D5 receptors, tavapadon may improve motor symptoms while reducing the risk of AEs linked to D2/D3 receptor overactivation.” (opens the source at this quote in a new tab)

Rationale for adjunctive use in motor fluctuations

“Tavapadon is a novel, oral, once-daily, selective D1/D5 agonist” (opens the source at this quote in a new tab)
“It is hypothesized that tavapadon can improve motor control with once-daily dosing, and may reduce the risk of specific AEs associated with D2/D3 receptor activation observed with currently available D2/D3 DAs.” (opens the source at this quote in a new tab)
“These findings highlight the clinical utility of adjunctive tavapadon for the treatment of PD with off fluctuations.” (opens the source at this quote in a new tab)

Background and interpretation of the flexible-dose monotherapy trial

“Current dopaminergic therapies for Parkinson’s disease carry significant limitations: levodopa can cause long-term motor complications, while D2/D3 receptor-targeting dopamine agonists can produce non-motor adverse effects.” (opens the source at this quote in a new tab)
“Although a broad range of investigative therapies are in development for symptomatic treatment of Parkinson’s disease, many recent trials have focused on the treatment of advanced Parkinson’s disease, and few novel therapies have been approved for monotherapy in early-stage Parkinson’s disease.” (opens the source at this quote in a new tab)
“A key unmet need for Parkinson’s disease is the availability of treatment modalities that provide a balance of dopamine signalling to improve motor symptoms while reducing the risk of specific adverse events associated with current D2/D3 receptor-targeting dopamine agonists.” (opens the source at this quote in a new tab)
“Tavapadon showed significant and clinically meaningful improvements in Parkinson’s disease motor symptoms, with low incidence of somnolence and impulse control disorders. However, the short observation period limits conclusions about long-term tolerability.” (opens the source at this quote in a new tab)
“The results of TEMPO-2, alongside the evidence from the TEMPO-1 and TEMPO-3 trials, provide a comprehensive body of evidence supporting the efficacy of tavapadon across the different stages of Parkinson’s disease.” (opens the source at this quote in a new tab)
“More data are required to compare tavapadon with approved D2/D3 dopamine agonists.” (opens the source at this quote in a new tab)

Pharmacological rationale for D1/D5 partial agonism

“Tavapadon, a highly selective partial agonist at D1 and D5 receptors, is being investigated for early through advanced PD” (opens the source at this quote in a new tab)
“First, by acting on D1/D5 dopamine receptors, tavapadon selectively activates direct pathway MSNs, which may provide stronger relief of motor symptoms than D2/D3-selective DAs” (opens the source at this quote in a new tab)
“The partial D1/D5 agonism provided by tavapadon may also reduce the probability of receptor desensitization, increasing the likelihood of sustained treatment benefit” (opens the source at this quote in a new tab)
“If ongoing phase 3 trials confirm the safety and efficacy of tavapadon as a monotherapy and adjunct to levodopa, the future availability of a D1/D5-selective agonist may provide another tool for physicians to manage symptoms and AEs for patients with PD” (opens the source at this quote in a new tab)

Certainty of evidence for the D1/D5 partial agonist class

“In early-stage monotherapy, tavapadon improved the combined MDS-UPDRS Parts II and III score by 10.55 points versus placebo (95% CI − 13.11 to − 7.99; two trials).” (opens the source at this quote in a new tab)
“In levodopa-treated patients with motor fluctuations, good ON-time increased by 1.09 h per day (0.57 to 1.61; two trials).” (opens the source at this quote in a new tab)
“Impulse control disorder (RR 2.02, 0.51 to 8.00; nine events, one trial) and somnolence (1.20, 0.37 to 3.92) were rated at very low certainty.” (opens the source at this quote in a new tab)
“Its proposed neuropsychiatric advantage over D2/D3 agonists remains untested: no trial used an active comparator or exceeded 27 weeks.” (opens the source at this quote in a new tab)

Positioning against existing dopamine agonists and adjuncts in a meta-analysis

“When viewed alongside the existing literature, the efficacy observed with tavapadon appears broadly comparable to that reported for established dopamine agonists.” (opens the source at this quote in a new tab)
“This magnitude of improvement is clinically meaningful and is broadly comparable to benefits reported for established adjunctive therapies such as opicapone, safinamide, and entacapone” (opens the source at this quote in a new tab)
“Discontinuation due to adverse events was, however, significantly more frequent with tavapadon (RR 2.72; 95% CI 1.07 to 6.96), and the substantial heterogeneity of that estimate (I² = 65.2%) indicates that tolerability is strongly influenced by titration strategy, patient population and adverse-event management. Tolerability, rather than serious harm, is therefore the principal safety consideration for clinical use.” (opens the source at this quote in a new tab)
“On present evidence that profile is untested, and the class cannot yet be preferred on neuropsychiatric grounds.” (opens the source at this quote in a new tab)
“Longer-term, adequately powered, head-to-head comparative studies are necessary before its place within treatment algorithms can be defined.” (opens the source at this quote in a new tab)

Positioning against D2 agonists and levodopa in a commentary on TEMPO-2

“Despite this clear positive efficacy signal, TEMPO-2 does not answer some essential questions that are mandatory to anticipate the future positioning of tavapadon among other antiparkinsonian dopaminergic options in clinical practice, especially D2 agonists and L-DOPA.” (opens the source at this quote in a new tab)
“Such an apparent safer profile of tavapadon on drug-induced somnolence is not trivial, especially for drivers carrying the risk of falling asleep at the wheel and people with similar attention-demanding jobs.” (opens the source at this quote in a new tab)
“In summary, adding a D1 agonist into the panel of available dopaminergic antiparkinsonian medications has been long awaited. Tavapadon could fill this gap. It is, however, too early to ascertain whether its benefit–risk ratio will represent a real step forward compared with outdated, off-patent, and cheap D2 agonists, justifying a commercially viable pricing and ultimately a rightful renewed interest in using dopamine agonists to treat patients with Parkinson’s disease.” (opens the source at this quote in a new tab)

Tavapadon among emerging therapies for motor fluctuations

“Preliminary results of a phase III study of dopamine D1/D5 agonist tavapadon and phase II of CVN424, a GRP6 inverse agonist suggest improved ON time.” (opens the source at this quote in a new tab)
“Overall, it is unclear whether the field is significantly further ahead, as the benefit of these emerging drugs in comparison with currently available agents for motor fluctuations needs to be clarified.” (opens the source at this quote in a new tab)

Potential role where dopamine agonist withdrawal is a concern

“Development of new generation DAs, such as tavapadon, which may reduce the side effects of dopaminergic therapy, may set new standards for treatment.” (opens the source at this quote in a new tab)
“The introduction of next-generation DAs (now still in clinical trials) like tavapadon, which focuses on more selective receptor targeting to reduce side effects, and being a D1/D5 partial agonist, shows promise for fewer side effects, including DAWS, as well as ICD and sleepiness, when compared to older D2/D3 agonists” (opens the source at this quote in a new tab)

Care setting: specialist input when fluctuations develop

“If a person with Parkinson's disease has developed dyskinesia and/or motor fluctuations, including medicines 'wearing off', seek advice from a healthcare professional with specialist expertise in Parkinson's disease before modifying therapy.” (opens the source at this quote in a new tab)

Anticipated uptake after approval

“The drug tavapadon, which AbbVie gained access to through its $8.7 billion acquisition of Cerevel Therapeutics in 2023, comes as a once-a-day pill.” (opens the source at this quote in a new tab)
“Citi analysts had previously said the launch was expected in the third quarter of 2026, but that uptake was likely to be gradual as negotiations progressed on the drug’s Medicare coverage.” (opens the source at this quote in a new tab)